# The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection

> **NCT04766931** · PHASE1 · COMPLETED · sponsor: **Frontier Biotechnologies Inc.** · enrollment: 88 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** FB2001
- **DRUG:** FB2001 Placebo

## Key facts

- **NCT ID:** NCT04766931
- **Lead sponsor:** Frontier Biotechnologies Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-17
- **Primary completion:** 2022-08-12
- **Final completion:** 2022-08-12
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2022-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04766931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04766931, "The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04766931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*